Please login to the form below

Not currently logged in
Email:
Password:

Gilead

This page shows the latest Gilead news and features for those working in and with pharma, biotech and healthcare.

Green light for Amgen’s KRAS inhibitor in the UK

Green light for Amgen’s KRAS inhibitor in the UK

In response to the announcement of the early access scheme, cancer charity Breast Cancer NOW has criticised Gilead for failing to follow suit with Trodelvy (sacituzumab govitecan) in triple negative incurable ... Gilead’s proposed pre-reimbursement

Latest news

More from news
Approximately 191 fully matching, plus 394 partially matching documents found.

Latest Intelligence

  • Setting up for success in a post-Brexit, post-pandemic Britain Setting up for success in a post-Brexit, post-pandemic Britain

    and running, ahead of our UK marketing authorisation in IBD, through our partnership with Gilead. ... With a focus on inflammatory and fibrotic conditions, we have submitted a marketing application through our partnership with Gilead for a new treatment

  • Sourcing R&D innovation: why pharma companies need to evolve their business models Sourcing R&D innovation: why pharma companies need to evolve their business models

    and. CAR-T therapies. Gilead’s acquisition of Kite Pharma and Bristol-Myers Squibb’s acquisition of Juno Therapeutics, as well as the merger and acquisition agreements between Novartis/Spark and

  • The search for effective drug treatments for COVID-19 The search for effective drug treatments for COVID-19

    The European Commission has signed a joint procurement agreement for Gilead’s COVID-19 antiviral treatment remdesivir. ... Since January, Gilead has taken multiple steps to ramp up production and rapidly build supply in recognition of the lengthy

  • Switzerland: a life sciences hub Switzerland: a life sciences hub

    The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.

  • Working together against COVID-19 Working together against COVID-19

    There were questions asked directly to Gilead, and also peers, about Compassionate Use and Extended Access. ... Subsequently, Gilead dropped remdesivir’s orphan drug designation based on its potential as a coronavirus treatment.

More from intelligence
Approximately 5 fully matching, plus 53 partially matching documents found.

Latest appointments

More from appointments
Approximately 6 fully matching, plus 21 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 14 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Life Healthcare Communications

Life is a creative communications agency offering multi-channel solutions for the healthcare industry. We use a storytelling approach to turn...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...